
    
      The salvage therapy in the patients with DLBCL is still controversial. The investigators
      conducted this study to evaluate the efficacy and tolerability of Rituximab combined with
      ESHAP in the patients with DLBCL. The patients enrolled were defined to be relapsed or
      refractory after the first-line chemotherapy like CHOP or other CHOP-like regimens.
    
  